Back

OliX expands OLX104C hair-loss trial to New Zealand, raising enrollment target to 158

Verifying
  • OliX Pharmaceuticals is adding New Zealand to the OLX104C hair-loss trial from Phase 2a.
  • Enrollment rises to 158 patients from 120, with four New Zealand institutions added.
  • OliX began Australian Phase 1b dosing in December last year and completed final-patient follow-up in August.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.